PURPOSE: To evaluate serum soluble Flt-1 (sFlt-1) in age-related macular degeneration (AMD) patients. DESIGN: Case-control study. METHODS: Study involved 56 non-AMD participants, 53 early AMD patients, and 97 neovascular AMD patients from Belfast in Northern Ireland. Serum samples were collected from each patient. Serum sFlt-1 was measured by human sVEGFR1/sFlt-1 ELISA kit. The results were analyzed by Excel and SPSS. RESULTS: Serum sFlt-1 concentration of non-AMD, early AMD, and neovascular AMD were 90.8 ± 2.9 pg/mL (± standard error of the mean), 88.2 ± 2.6 pg/mL, and 79.9 ± 2.2 pg/mL. sFlt-1 from neovascular AMD patients was significantly decreased compared to non-AMD and early AMD patients (ANOVA, P < .01). For each 10-point increase in sFlt-1, the odds for having neovascular AMD compared with non-AMD and neovascular AMD decrease by 27.8%, odds ratio (OR) = 0.722 (95% confidence interval [CI]: 0.588-0.888, P = .002) and 27.0%, OR = 0.730 (95% CI: 0.594-0.898, P = .003), respectively. In patients over 73 years of age, serum sFlt-1 <80 pg/mL was associated with a >6-fold higher risk of neovascular AMD. CONCLUSIONS: Reduced serum sFlt-1 differentiates those patients with neovascular AMD from both early AMD and non-AMD participants. In those aged over 73, serum sFlt <80 pg/mL seems to indicate a particularly high risk of neovascular AMD. Our results indicate serum sFlt-1 could be a biomarker for development of neovascular AMD.
PURPOSE: To evaluate serum soluble Flt-1 (sFlt-1) in age-related macular degeneration (AMD) patients. DESIGN: Case-control study. METHODS: Study involved 56 non-AMDparticipants, 53 early AMDpatients, and 97 neovascular AMDpatients from Belfast in Northern Ireland. Serum samples were collected from each patient. Serum sFlt-1 was measured by human sVEGFR1/sFlt-1 ELISA kit. The results were analyzed by Excel and SPSS. RESULTS: Serum sFlt-1 concentration of non-AMD, early AMD, and neovascular AMD were 90.8 ± 2.9 pg/mL (± standard error of the mean), 88.2 ± 2.6 pg/mL, and 79.9 ± 2.2 pg/mL. sFlt-1 from neovascular AMDpatients was significantly decreased compared to non-AMD and early AMDpatients (ANOVA, P < .01). For each 10-point increase in sFlt-1, the odds for having neovascular AMD compared with non-AMD and neovascular AMD decrease by 27.8%, odds ratio (OR) = 0.722 (95% confidence interval [CI]: 0.588-0.888, P = .002) and 27.0%, OR = 0.730 (95% CI: 0.594-0.898, P = .003), respectively. In patients over 73 years of age, serum sFlt-1 <80 pg/mL was associated with a >6-fold higher risk of neovascular AMD. CONCLUSIONS: Reduced serum sFlt-1 differentiates those patients with neovascular AMD from both early AMD and non-AMDparticipants. In those aged over 73, serum sFlt <80 pg/mL seems to indicate a particularly high risk of neovascular AMD. Our results indicate serum sFlt-1 could be a biomarker for development of neovascular AMD.
Authors: Emily Y Chew; Traci E Clemons; Susan B Bressler; Michael J Elman; Ronald P Danis; Amitha Domalpally; Jeffrey S Heier; Judy E Kim; Richard Garfinkel Journal: Ophthalmology Date: 2013-11-08 Impact factor: 12.079
Authors: Nathan Congdon; Benita O'Colmain; Caroline C W Klaver; Ronald Klein; Beatriz Muñoz; David S Friedman; John Kempen; Hugh R Taylor; Paul Mitchell Journal: Arch Ophthalmol Date: 2004-04
Authors: Lebriz Ersoy; Tina Ristau; Moritz Hahn; Marcus Karlstetter; Thomas Langmann; Katharina Dröge; Albert Caramoy; Anneke I den Hollander; Sascha Fauser Journal: Invest Ophthalmol Vis Sci Date: 2014-03-25 Impact factor: 4.799
Authors: Manuel M Hermann; Freekje van Asten; Philipp S Muether; Dzenita Smailhodzic; Peter Lichtner; Carel B Hoyng; Bernd Kirchhof; Christian Grefkes; Anneke I den Hollander; Sascha Fauser Journal: Ophthalmology Date: 2013-12-21 Impact factor: 12.079
Authors: Ling Luo; Hironori Uehara; Xiaohui Zhang; Subrata K Das; Thomas Olsen; Derick Holt; Jacquelyn M Simonis; Kyle Jackman; Nirbhai Singh; Tadashi R Miya; Wei Huang; Faisal Ahmed; Ana Bastos-Carvalho; Yun Zheng Le; Christina Mamalis; Vince A Chiodo; William W Hauswirth; Judit Baffi; Pedro M Lacal; Angela Orecchia; Napoleone Ferrara; Guangping Gao; Kim Young-Hee; Yingbin Fu; Leah Owen; Romulo Albuquerque; Wolfgang Baehr; Kirk Thomas; Dean Y Li; Kakarla V Chalam; Masabumi Shibuya; Salvatore Grisanti; David J Wilson; Jayakrishna Ambati; Balamurali K Ambati Journal: Elife Date: 2013-06-18 Impact factor: 8.140
Authors: Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati Journal: Prog Retin Eye Res Date: 2016-05-06 Impact factor: 21.198
Authors: Kathleen R Chirco; Carly J Lewis; Todd E Scheetz; Rebecca M Johnston; Budd A Tucker; Edwin M Stone; John H Fingert; Robert F Mullins Journal: Ophthalmic Genet Date: 2017-09-26 Impact factor: 1.803
Authors: Ian J Constable; Cora M Pierce; Chooi-May Lai; Aaron L Magno; Mariapia A Degli-Esposti; Martyn A French; Ian L McAllister; Steve Butler; Samuel B Barone; Steven D Schwartz; Mark S Blumenkranz; Elizabeth P Rakoczy Journal: EBioMedicine Date: 2016-11-10 Impact factor: 8.143